AstraZeneca PLC (AZN)vsTransMedics Group Inc (TMDX)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
TMDX
TransMedics Group Inc
$92.00
-0.01%
HEALTHCARE · Cap: $3.16B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8473% more annual revenue ($62.38B vs $727.65M). TMDX leads profitability with a 19.9% profit margin vs 17.7%. TMDX appears more attractively valued with a PEG of 0.80. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
TMDX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Margin of Safety
+56.3%
Fair Value
$304.76
Current Price
$92.00
$212.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Every $100 of equity generates 35 in profit
Revenue surging 41.1% year-over-year
Growing faster than its price suggests
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
Elevated debt levels
Earnings declined 29.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : TMDX
The strongest argument for TMDX centers on Return on Equity, Revenue Growth, PEG Ratio. Profitability is solid with margins at 19.9% and operating margin at 13.9%. Revenue growth of 41.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TMDX
The primary concerns for TMDX are Altman Z-Score, Debt/Equity, EPS Growth. Debt-to-equity of 1.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while TMDX is a growth play — different risk/reward profiles.
TMDX carries more volatility with a beta of 2.10 — expect wider price swings.
TMDX is growing revenue faster at 41.1% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 62/100), backed by strong 17.7% margins. TMDX offers better value entry with a 56.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TransMedics Group Inc
HEALTHCARE · MEDICAL DEVICES · USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?